FDA warning letters to foreign manufacturers jump 40%; Novartis turns to CMO to meet demands;

> The FDA sent 52 GMP warning letters in the last 12 months, and 40% of those were to manufacturing plants outside the U.S. Story

> Novartis ($NVS) is using some contract manufacturing operations to help it meet drug demands while its plant in Nebraska continues remediation. Story

> The FDA has sent letters to more than four dozen doctors and medical practices in the U.S. warning them they may have purchased counterfeit Avastin, which, if used, could harm patients. Story

> Spectrum Pharmaceuticals ($SPPI) says it has increased its manufacturing capacity for cancer treatment Fusilev (levoleucovorin) for injection. Item

> Novasep, which makes pharma purification systems, has named Jean-Claude Romain director of quality and placed him on the company's executive committee. Release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.